About: Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Creator	Azoulay, Elie Darmon, Michael Lemiale, Virginie Bauer, Philippe Van De Louw, Andry Meert, Anne-Pascale Vincent, François
Source	PMC
abstract	Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have entered routine practice for the treatment of many cancers. They improve the outcome for many cancers, and more patients will be treated with CPI in the future. Although CPI can lead to adverse events (AE) less frequently than for chemotherapy, their use can require intensive care unit admission in case of severe immune-related adverse events (IrAE). Moreover, some of these events, particularly late events, are poorly documented, so a high level of suspicion should be maintained for patients receiving CPI. Intensivists should be aware in general of the known complications and appropriate management of these AE. Nevertheless, a multidisciplinary collaboration remains essential for their diagnosis and management. This review described the most severe complications related to CPI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13613-019-0487-x) contains supplementary material, which is available to authorized users.
has issue date	2019-02-01(xsd:dateTime)
bibo:doi	10.1186/s13613-019-0487-x
bibo:pmid	30707321
has license	cc-by
sha1sum (hex)	0f08775834cff481a195a4926a29cf718918c1f2
schema:url	https://doi.org/10.1186/s13613-019-0487-x
resource representing a document's title	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
has PubMed Central identifier	PMC6358632
has PubMed identifier	30707321
schema:publication	Ann Intensive Care
resource representing a document's body	covid:0f08775834cff481a195a4926a29cf718918c1f2#body_text
is schema:about of	named entity 'essential' named entity 'diagnosis' named entity 'collaboration' named entity 'inhibitor' named entity 'patients' named entity 'CPI' named entity 'physicians' named entity 'inhibitors' named entity 'intensive care' covid:arg/0f08775834cff481a195a4926a29cf718918c1f2 named entity 'antibodies' named entity 'complications' named entity 'inhibitors' named entity 'case' named entity 'inhibitors' named entity 'aware' named entity 'events' named entity 'They' named entity 'neurological' named entity 'corticosteroids' named entity 'acute respiratory failure' named entity 'ipilimumab' named entity 'hematological malignancies' named entity 'Viral hepatitis' named entity 'C. difficile' named entity 'conventional treatment' named entity 'chronic liver disease' named entity 'cardiomyopathy' named entity 'ketosis' named entity 'PD-1' named entity 'chemotherapy' named entity 'ligand' named entity 'melanoma' named entity 'etiologies' named entity 'chemotherapy' named entity 'steroid' named entity 'carcinoma' named entity 'Hashimoto's disease' named entity 'neurotoxicity' named entity 'hepatitis' named entity 'PD-1' named entity 'acute respiratory distress syndrome' named entity 'autoimmune diseases' named entity '1, 2' named entity 'adverse events' named entity 'antinuclear antibodies' named entity 'sampling error' named entity 'PDL1' named entity 'colitis' named entity 'perforation' named entity 'lung biopsy' named entity 'pancreatitis' named entity 'monotherapy' named entity 'hypersensitivity' named entity 'cardiomyocytes' named entity 'AKI' named entity 'PDL1' named entity 'kidney biopsy' named entity 'myocarditis' named entity 'toxic effects' named entity 'abdominal pain' named entity 'lesion' named entity '14.5' named entity 'hypothyroidism' named entity 'clinical presentation' named entity 'Seizures' named entity 'nausea' named entity 'dyspnea' named entity 'Shirali' named entity 'malignancies' named entity 'programmed cell death protein 1' named entity 'inter-study heterogeneity' named entity 'ipilimumab' named entity 'infectious diseases' named entity 'toxicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software